

Aurealis Pharma Completes 3.3MCHF Seed C Financing to Advance Its Multitherapy Biologics

Basel Switzerland, Kuopio Finland – January 7th 2016.

Aurealis Pharma, a privately owned biopharmaceutical company co-located in Switzerland and Finland focused on developing novel lactic acid bacteria based multitherapy biologics for patients with chronic inflammation and cancer, announced today the successful closing of 3.3MCHF funding provided by Swiss and Finnish private investors and Finnvera plc, a specialized financing company owned by the State of Finland.

“We are extremely happy to successfully complete our Seed C financing round with an oversubscription of shares showing strong demand, and warmly welcome our new Swiss investors with their valuable expertise and networks. We are committed to continue our aspirations in the region, one of the major global biotech and pharma hubs. We also acknowledge the continuous support from our existing investor Finnvera plc, who has been fundamental as company’s early investor” stated CEO Juha Yrjänheikki.

“An experienced and ambitious team who is able to deliver, combined with a sound scientific rationale, a disruptive new technology and a lead product with impressive preclinical efficacy data were key factors to gain the attention of the Swiss investment community and subsequently internationalize Aurealis Pharma’s investor base” said Mr. Roger Meier of Clarena AG, representing the Swiss investors.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma

Tel: +358 45 8433550

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)

www.aurealispharma.com



AUREALIS PHARMA

Microkatu 1 Greifengasse 11
FI-70210 Kuopio CH-4058 Basel
Finland Switzerland
www.aurealispharma.com